Wednesday, July 8, 2026

pharma · Anemia · Anemia Associated With Chronic Kidney Disease · AKBA

Akebia Europe

Akebia Europe is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AKBA. Primary therapeutic focus areas include Anemia, Anemia Associated With Chronic Kidney Disease, Anemia of Chroni

Cambridge, USA HQ
2007 Founded
271 Employees
Public company Type
AKBA · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2007
Employees
271
Programs
25
Drugs
13
Patents
28
Clinical program

Vadadustat

Phase 2 · small molecule · Chronic Kidney Disease

Vadadustat for Chronic Kidney Disease is a Phase 2 program (small_molecule) at Akebia Europe Limited with 1 ClinicalTrials.gov record(s).

← All Akebia Europe Limited projects Phase 2 small molecule completed

Internal code AKB-6548-CI-0003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Akebia Europe Limited
Phase
Phase 2
Modality
small_molecule
Indication
Chronic Kidney Disease
Status
completed
Trials
1